Myriad Genetics (NASDAQ:MYGN) Stock Gets Price Target Increase from TD Cowen

Myriad Genetics (NASDAQ:MYGN) had its price objective boosted by TD Cowen from $4.50 to $6.75 in a report released on Thursday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. TD Cowen‘s price target suggests a potential upside of 14.02% from the company’s previous close.

A number of other research analysts have also issued reports on the company. Zacks Research upgraded Myriad Genetics from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 15th. Stephens cut their price target on shares of Myriad Genetics from $5.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday, August 18th. Weiss Ratings cut shares of Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 27th. UBS Group started coverage on shares of Myriad Genetics in a report on Wednesday, September 9th. They set a “neutral” rating and a $3.60 price objective on the stock. Finally, Leerink Partners lifted their target price on shares of Myriad Genetics from $5.00 to $8.00 and gave the company a “market perform” rating in a research report on Thursday. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Myriad Genetics currently has a consensus rating of “Hold” and a consensus target price of $5.55.

Myriad Genetics Price Performance

Shares of Myriad Genetics stock traded down $0.37 on Thursday, hitting $5.92. The company’s stock had a trading volume of 2,562,310 shares, compared to its average volume of 3,077,596. The company has a market capitalization of $566.25 million, a price-to-earnings ratio of -4.35 and a beta of 1.62. Myriad Genetics has a 1 year low of $2.74 and a 1 year high of $8.09. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.21. The firm has a fifty day moving average price of $4.50 and a 200-day moving average price of $4.62.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. Myriad Genetics had a negative return on equity of 16.09% and a negative net margin of 13.96%. The company had revenue of $202.70 million for the quarter, compared to the consensus estimate of $191.33 million. As a group, sell-side analysts anticipate that Myriad Genetics will post -0.99 earnings per share for the current fiscal year.

Institutional Trading of Myriad Genetics

Several large investors have recently made changes to their positions in MYGN. Orbimed Advisors LLC acquired a new position in Myriad Genetics in the 1st quarter valued at $562,500,000. BlackRock Inc. purchased a new position in Myriad Genetics in the 2nd quarter valued at $62,184,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Myriad Genetics during the 2nd quarter worth $8,039,000. Man Group plc acquired a new stake in Myriad Genetics during the 2nd quarter worth $5,189,000. Finally, Bank of America Corp DE purchased a new stake in shares of Myriad Genetics during the second quarter worth $5,150,000. 99.02% of the stock is currently owned by hedge funds and other institutional investors.

More Myriad Genetics News

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Myriad reported Q3 revenue of $202.7 million, above analysts’ $191.33 million estimate, and a loss of $0.11 per share—narrower than the expected $0.20 loss. The company also raised the midpoint of its FY2026 revenue outlook to a range of $780 million–$790 million. Article: Myriad Genetics Raises FY26 Revenue Outlook Midpoint
• Positive Sentiment: TD Cowen raised its price target to $6.75 from $4.50, while retaining a Hold rating; Leerink Partners raised its target to $8 from $5, with a Market Perform rating. Higher targets suggest improved expectations, though neither firm upgraded its rating. Article: TD Cowen price target
• Neutral Sentiment: Myriad agreed to sell its Prenatal Health business for $210 million. The proceeds could support the company’s finances and focus, but the divestiture also changes its revenue base; the outlook is presented following the sale. Article: Myriad outlines 2026 outlook following divestiture
• Negative Sentiment: The company said it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. Potential exposure of sensitive information or disruption creates uncertainty and could be contributing to investor concern. Article: Myriad reports cybersecurity incident

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.